MIT Researchers Develop Lipid Nanoparticle That Reduces mRNA Vaccine Dosage by Up to 100 Times

Researchers at the Massachusetts Institute of Technology (MIT) have developed a new lipid nanoparticle (LNP) that significantly improves the delivery and effectiveness of mRNA vaccines. The study indicates that this innovation could reduce the required dosage for mRNA-based vaccines by up to 100 times, potentially lowering production costs and increasing accessibility. The findings suggest that these particles enhance the potency of mRNA technology, which is widely used in vaccines such as those for COVID-19.

The research focused on optimizing LNPs, which are microscopic carriers designed to deliver genetic material into cells effectively. By engineering these nanoparticles, scientists were able to boost their efficiency in transporting mRNA molecules into target cells. This improvement allows for smaller doses of mRNA to achieve the same immune response as higher doses currently used in vaccine formulations. Lower dosages could lead to reduced manufacturing expenses and make distribution more feasible on a global scale. The study highlights how advancements in nanotechnology may play a critical role in improving vaccine development and delivery systems moving forward.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: November 7, 2025

Related posts:

Sanofi Acquires Vigil Neuroscience for $470 Million to Advance Neurodegenerative Disease Treatments Diabetes Drug Linked to Reduced Prostate Cancer Recurrence in International Study FDA Launches Rare Disease Endpoint Advancement Program and Bespoke Gene Therapy Consortium Adaptive AI Framework Utilizing GATs and AutoML Developed to Predict Drug Pharmacokinetics

Author

GOAI